INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2021

Nicotinamide mononucleotide supplementation increased muscle insulin sensitivity and insulin signaling in postmenopausal women with prediabetes.

A 10-week, randomized, placebo-controlled, double-blind trial evaluated the effects of nicotinamide mononucleotide (NMN) supplementation on metabolic function in overweight or obese postmenopausal women with prediabetes. Insulin-stimulated glucose disposal, evaluated using a hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling (AKT and mTOR phosphorylation) increased after NMN supplementation but did not change after placebo. Additionally, NMN supplementation up-regulated platelet-derived growth factor receptor β and other genes involved in muscle remodeling.

Study type
10-week randomized, placebo-controlled, double-blind trial
Who was studied
Postmenopausal women with prediabetes who were overweight or obese
What was measured
Insulin-stimulated glucose disposal, skeletal muscle insulin signaling, and muscle remodeling gene expression

THE PAPER

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Science, 2021.

PubMed 33888596 ↗DOI 10.1126/science.abe9985 ↗

Diabetes & blood sugarNutrients & adequacyWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.